LPCN 1148 | Pharmasources.com
We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
I Agree
  • FDA Clears LPCN 1148 IND Application for Phase 2 Cirrhosis Trial americanpharmaceuticalreview
    May 06, 2020
    Lipocine announced that the U.S. Food & Drug Administration (FDA) has accepted the Company's Investigational New Drug application (IND) to initiate a Phase 2 proof-of-concept study to evaluate the therapeutic potential of LPCN 1148.
PharmaSources Customer Service